Second malignancy in patients with Hodgkin's disease treated at the Royal Marsden Hospital. by Swerdlow, A. J. et al.
British Joumal ofCancer(1997) 75(1), 116-123
© 1997 Cancer Research Campaign
Second malignancy in patients with Hodgkin's disease
treated at the Royal Marsden Hospital
AJ Swerdlow1, JA Barber1, A Horwich2, D Cunningham3, S Milan3 and RZ Omar'
'Epidemiological Monitoring Unit, Department of Epidemiology & Population Sciences, London School of Hygiene & Tropical Medicine, Keppel Street,
London WCIE 7HT UK; 2Academic Unit of Radiotherapy & Oncology, The Institute of Cancer Research & Royal Marsden Hospital, Downs Road, Sutton,
Surrey, UK; 3Lymphoma Unit, The Institute of Cancer Research & Royal Marsden Hospital, Downs Road, Sutton, Surrey, UK
Summary Risk of second primary malignancy was assessed in follow-up to June 1991 of 1039 patients first treated for Hodgkin's disease at
the Royal Marsden Hospital during 1963-91. A total of 77 second malignancies occurred. There were significantly raised risks of stomach
[standardized incidence ratio (SIR)=4.0], lung (SIR=3.8), bone (SIR=26.5), softtissue (SIR=16.9) and non-melanoma skin (SIR=3.9) cancers,
non-Hodgkin's lymphoma (SIR=4.6), and acute and non-lymphocytic leukaemia (SIR=31.3), with a relative risk of 3.3 for all second cancers
other than non-melanoma skin cancer. Solid cancer risk was raised to a similar extent in patients treated only with radiotherapy (SIR=2.6,
P<0.001), only with chemotherapy (SIR=2.1, P=0.08) and with both (SIR=3.1, P<0.001). Leukaemia risk was raised only in those receiving
chemotherapy, whether alone or with radiotherapy. The relative risk for solid cancers was much greater in patients who were younger at first
treatment (trend P<0.001), whereas leukaemia risk was greatest for those first treated at ages 25-44. For solid cancers (P<0.001) but not
leukaemia (P=0.05) there was a strong gradient of greater relative risks at younger attained ages. The relative risk of second cancers overall
was 27.5 at ages under 25 and 2.0 at ages 55 and above. Leukaemia and solid cancer risks in patients treated with chlorambucil, vinblastine,
procarbazine and prednisone (ChIVPP) were not significantly greater than those in patients treated with mustine, vincristine, procarbazine
and prednisone (MOPP). Number of cycles of chemotherapy was significantly related to risk of leukaemia (P<0.001), and there was a trend
in the same direction for solid cancers (P=0.07). The study adds to evidence that alkylating chemotherapy may increase the risk of solid
cancers, and that ChIVPP does not provide a less carcinogenic alternative to MOPP chemotherapy. The very large relative risks found for
solid cancers at young attained ages and in patients treated when young may have important implications as, in the long term, the majority of
second malignancies after Hodgkin's disease are solid cancers. The risks of solid malignancies need clarification by larger collaborative
epidemiological studies.
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INTRODUCTION
The transformation in prognosis of Hodgkin's disease following
the introduction of intensive radiotherapy and chemotherapy
is one of the great successes of modem medicine, but it has
brought with it a raised risk of second malignancy. Acute or non-
lymphocytic leukaemia (ANLL) occurs in the first few years after
treatment, mainly as a consequence ofchemotherapy (Tucker et al,
1988; Kaldor et al, 1990; Swerdlow et al, 1992; van Leeuwen et al,
1994a; Boivin et al, 1995). The relation of an increased risk of
solid cancers to treatment, especially chemotherapy, is less clear.
Four recent papers have suggested that chemotherapy without
radiotherapy can lead to an increase in solid cancer risk (Kaldor et
al, 1992; Swerdlow, 1992; Biti et al, 1994; Boivin et al, 1995), but
other studies did not support this (Abrahamsen et al, 1993; van
Leeuwen et al, 1994a). The issue is important because in the long
term solid malignancies form the great majority of second cancers
after Hodgkin's disease.
As the acute and long-term side-effects of chemotherapy have
been more appreciated, various different chemotherapeutic regimens
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have been introduced in the hope ofreducing the incidence ofthese
effects. Information on the carcinogenicity of specific drugs and
combinations ofdrugs, and on therelationship ofintensity and dura-
tion of treatment to carcinogenicity has been limited, however, and
has been almost entirely in relation to leukaemia, not solid cancer
risk. The Royal Marsden Hospital (RMH) has been involved in
intensive treatment ofHodgkin's disease since the 1960s, when this
therapy was first used, and its database of patients treated, makes
available more than 25 years of follow-up. A previous publication
described secondmalignancies up to the end of 1983 inpatients first
treated before 1979 (Colman et al, 1988). The present analyses
extend the numbers and length of follow-up for Hodgkin's disease
patients attheRMH, and also extend therangeofanalyses ofrisks in
these patients, especially with regard to solid cancer.
MATERIALS AND METHODS
The RMH is one ofthe largest cancer treatment centres in the UK,
and its computerized databases contain details of treatment and
follow-up of Hodgkin's disease patients since 1963. For the
present analyses we extracted data on all patients first treated from
1963 to March 1991 by one of the two treatment teams at the
hospital, and from 1963 to February 1989 by the other team. We
updated treatment and follow-up data on these patients to 30 June
1991. The treatment data included information on the cycles of
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treatment since diagnosis, including treatments before first atten-
dance at the RMH. In some instances, the date of starting an indi-
vidual cycle was known, and in others only the date of starting a
course (ofseveral cycles) oftreatment; for the latter, we estimated
the dates ofindividual cycles from information on the start date of
the course, the number ofcycles in the course and the mean dura-
tion per cycle. Regular follow-up of Hodgkin's disease patients at
the RMH is conducted at least annually, unless the patient is trans-
ferred to another hospital, which then provided the available infor-
mation. To check that follow-up for second cancers was complete,
as well as examining case notes, we matched details of study
subjects against cancer registration records for the South Thames
Region, within which the RMH is situated, and extracted data on
second cancers from this source. The regional cancer registry
receives from the National Health Service Central Registers notifi-
cation of second malignancies occurring anywhere in the country
in patients resident in the registry region at the time of the initial
Hodgkin's disease. Pathological review of second cancers was
available where these had occurred while under follow-up at the
RMH, but for second cancers in patients followed up elsewhere,
the report from the current treatment centre was used. Patients
resident outside the UK were excluded from the analyses because
of incomplete follow up and the absence of appropriate data to
calculate expected cancer incidence rate.
For each patient in the cohort, person-years at risk of second
cancer by 5-year age group, sex and calendar year were calculated
from date of first treatment to 30 June 1991, or to the date of
death, second cancer incidence or loss to follow-up, if earlier. For
analyses oftime-dependent variables (e.g. interval since treatment
and number ofcycles oftreatment), subjects were assigned at each
stage of follow-up to the value of the variable applicable at that
time. Observed numbers of cancers in the cohort were compared
with expectations calculated by multiplying the person-years at
risk in the cohort in each age, sex and calendar yearcategory by the
corresponding cancer registration rates in the general population of
the South Thames region. As registration statistics were not
available in computer-readable form before 1971 or after 1989,
we applied 1971 data to give expecteds for 1963-71 and 1989 data
to giveexpecteds for 1989-91. Site ofsecond cancers was coded to
the International Classification of Diseases (ICD) (WHO, 1978)
revisions in force in England and Wales at the time ofoccurrence:
ICD7 for 1963-67, ICD8 for 1968-78, and ICD9 for 1979
onwards. We reallocated the data coded to the earlier revisions
('bridge-coded' the data) to the ICD9 categories shown in Table 1.
Standardized incidence ratios (SIRs) were then calculated as the
ratio of observed to expected numbers of cancers. Ninety-five per
cent confidence interval estimates for the SIRs were calculated
using a likelihood-based method (Clayton and Hills, 1993). Site-
specific absolute excess risks of second cancer were calculated by
subtracting expected from observed numbers and dividing by
person-years at risk. Cumulative (actuarial) probabilities ofsecond
cancer were calculated by the method ofKaplan and Meier (1958).
To compare risks in different treatment groups, with adjust-
ment for possible confounding variables such as age at first treat-
ment or number of cycles of treatment, relative risks were
calculated by Cox regression (Cox, 1972). All significance levels
are two-sided.
RESULTS
A total of 1039 patients (649 men, 390 women) met the study
criteria and were included in the cohort. Most (79%) were aged
under45 years atfirst treatment, ranging from 3 to 84 years. During
follow-up 77 patients developed a second malignancy and, of the
remainder, 332 died, 20 emigrated, four were lost to follow-up and
606 survived to the end of June 1991. The follow-up was for 9516
person-years in total, an average of9.1 years per cohort member.
As well as 77 second malignancies during follow-up, there were
two in situ tumours of the cervix and two of the skin, one benign
parotid tumour and one brain tumour ofunspecified nature, which
Table 1 Relative risks of second primary cancer of selected sites
ICD9 Site No. SIR (95% Cl) Absolute excess risk per
10 000 person-years
141-9 Tongue, mouth and pharynx 2 5.7 (0.9-17.5) 1.7
151 Stomach 4 4.0 (1.2-9.3)* 3.2
154 Colon 2 1.4 (0.2-4.4) 0.6
162 Lung 15 3.8 (2.2-6.0)... 11.6
170 Bone 2 26.5 (4.4-81.8)" 2.0
171 Soft tissue 2 16.9 (2.8-52.3)" 2.0
172 Malignant melanoma 2 4.0 (0.7-12.2) 1.6
173 Non-melanoma skin cancer 10 3.9 (1.9-6.8)... 7.8
175 Breast (female) 5 1.8 (0.7-3.9) 2.4
184 Prostate 2 2.1 (0.4-6.5) 1.1
193 Thyroid 1 8.2 (0.5-36.0) 0.9
195-9 Unknown primary 3 3.5 (0.9-9.1) 2.3
200, 202 Non-Hodgkin's lymphoma 3 4.6 (1.2-12.0)* 2.5
204-8 All leukaemia 13 23.5 (12.9-38.6)*.. 13.1
204.0, 204.2-208.9 Leukaemia other than chronic 12 31.3 (16.7-52.4)*** 12.2
lymphoid leukaemia (CLL)
204.1 CLL 1 5.9 (0.3-25.8) 0.9
140-172, All malignancies except 67 3.3 (2.6-4.2)... 49.2
174-200, non-melanoma skin cancer
202-208 and Hodgkin's diseasea
*P<0.05; **P<0.01; ***P<0.001. alncludes, apart from the tumours above, one cancer of the lip, one of the oesophagus, one rectum, one pancreas,
one unspecified digestive, one cervix, one corpus uteri, one testis, two bladder, one brain.
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Table 2 Cumulative (actuarial) risks of second primary cancer
All other solid tumours All malignancies except Hodgkin's
Lung cancer excluding non-melanoma Leukaemia disease and non-melanoma skin
skin cancer cancer
Years since first % probability (95% Cl) % probability (95% Cl) % probability (95% Cl) % probability (95% Cl)
treatment
5 0.2 (0.1-0.9) 1.9 (1.1-3.2) 0.6 (0.3-1.5) 2.7 (1.8-4.1)
10 1.3 (0.6-2.6) 3.6 (2.4-5.3) 1.9 (1.1-3.4) 6.9 (5.2-9.2)
15 3.0 (1.7-5.1) 5.2 (3.5-7.6) 1.9 (1.1-3.4) 10.3 (7.9-13.3)
20 3.4 (2.0-5.8) 8.3 (5.5-12.5) 2.3 (1.3-4.2) 14.0 (10.6-18.4)
Table 3 Relative risks of second primary cancer by treatment group
All other solid cancers, All malignancies except
Lung cancer excluding non-melanoma skin Leukaemia Hodgkin's disease and
cancer non-melanoma skin cancer
Treatment group No. SIR (95% Cl) No. SIR (95% Cl) No. SIR (95% Cl) No. SIR (95% Cl)
Chemotherapy 3 3.9 (1.0-10.0) 4 1.6 (0.5-3.6) 5 50.4 (18.1-108.3)*** 12 3.3 (1.8-5.6)***
(person-years = 1531)
Radiotherapy 7 4.2 (1.8-8.1)* 14 2.2 (1.2-3.6)* 0 - 22 2.6 (1.6-3.8)*..
(person-years = 3660)
Combined 5 3.2 (1.2-6.9)- 18 3.0 (1.8-4.7)*** 8 34.9 (16.0-65.0)*** 33 4.1 (2.8-5.6)*..
(person-years = 4325)
All treatments 15 3.8 (2.2-6.0)... 36 2.4 (1.7-3.3)*** 13 23.4 (12.9-38.6)*.. 67 3.3 (2.6-4.2)***
(person-years = 9516)
*P<0.05; **P<0.01; ***P<0.001.
were not included in the analyses. One patient had a third cancer -
pancreatic cancer after bladder cancer - and this too was not
included in the analyses. No second cancers occurred in the first 6
months after treatment, suggesting that none had been incident but
undetected before Hodgkin's disease treatment started, and were
detected as a consequence ofit. Table 1 shows site-specific relative
risks of second cancer in the cohort. There was a more than three-
fold raised risk of cancer overall, with significantly raised risks of
lung, bone, soft tissue and non-melanoma skin cancers, non-
Hodgkin's lymphoma and acute and non-lymphoid leukaemia
(ANLL). Two-thirds of the absolute excess risk of cancer in the
cohort was due to solid tumours (Table 1), and one-third to lympho-
haematopoietic malignancies. In the remainder of this paper, non-
lung solid cancers are generally grouped because ofsmall numbers
at each site; non-melanoma skin cancers are omitted from the risk
calculations because the data on expected rates are less satisfactory
than forother sites (so that the all malignancy analyses are based on
the remaining 67 cases); and all leukaemias, rather than ANLL
separately, are analysed because reference rates are incomplete for
ANLL, as a proportion ofleukaemias recorded in the cancer regis-
tration data are ofunknown subtype.
Table 2 shows cumulative risks of second cancer in the cohort.
For all cancers except non-melanoma skin cancer, there was a
cumulative risk of 14% at 20 years, mainly reflecting the risk of
solid tumours (11%).
There were significantly raised risks of cancer overall for
patients treated with each modality (Table 3), but risk was greatest
for those given combined treatment (i.e. chemotherapy plus radio-
therapy). Lung cancer risks were three- to fourfold raised in each
treatment group, significantly after radiotherapy and combined
modalities, and borderline significantly (P=0.05) after chemo-
therapy, based on a smaller number of person-years. Non-lung
solid malignancy risks were also raised in each group, although
significant only in the two larger groups - radiotherapy and
combined-modality treatment. The relative risk for all solid
cancers after radiotherapy alone was 2.6 (1.7-3.9; P<0.001), after
chemotherapy alone 2.1 (0.9-4.1; P=0.08) and after combined
modality treatment 3.1 (2.0-4.5; P<0.001). Leukaemia risks were
greatly raised in chemotherapy and combined modality-treated
patients, but no cases occurred inpatients treated solely withradio-
therapy. Among non-lung solid tumours, there were significantly
raised risks of lip cancer (SIR=82.9) in radiotherapy patients,
stomach (SIR=7.7), soft tissue (SIR=38.6) and non-melanoma skin
(SIR=5.8) cancers in mixed-modality patients, and tongue cancer
(SIR=78.3) in chemotherapy patients.
Adjusting the treatment group comparisons in Table 3 for sex,
age at first treatment, yearoffirst treatment and duration since first
treatment by Cox regression (not shown in table), increased the
risks of solid cancers and of all cancers after chemotherapy alone
compared with after combined modalities or radiotherapy alone:
for all solid cancers, the adjusted relative risks for these three
treatment groups were 1.0, 1.0 (0.4-2.4) and 1.0 (0.4-2.4) respec-
tively, and for all cancers they were 1.0, 0.8 (0.4-1.6) and 0.6
(0.3-1.2). For leukaemia, the risk for combined-modality treat-
ment compared with chemotherapy alone was 0.4 (0.1-1.3), and
no cases occurred in patients treated solely with radiotherapy.
The relative risk of second malignancy overall was non-signifi-
cantly greater in men than women (P=0.6) (Table 4). There was a
non-significantly greater risk of non-lung solid cancers in men
than women, and of lung cancer and leukaemia in women than
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Table 4 Relative and absolute excess risks of second cancer by sex, and age at first treatment
All other solid cancers, All malignancies except
Lung cancer excluding non-melanoma Leukaemia Hodgkin's disease and
skin cancer non-melanoma skin cancer
No. SIR (95% Cl) ARa No. SIR (95% Cl) ARU No. SIR (95% Cl) AR" No. SIR (95% Cl) AR"
Sex
Male (n=649) 10 3.1 (1.6-5.5)* 12.0 21 2.8 (1.8-4.2)... 23.7 8 21.7 (9.9-40.5)*** 13.4 41 3.5 (2.5-4.7)*** 51.5
Female (n=390) 5 6.3 (2.3-13.6)* 11.0 15 2.1 (1.2-3.3)* 20.2 5 26.8 (9.6-57.6)*** 12.6 26 3.0 (2.0-4.4)*** 45.6
Age (years)
<25 (n=377) 2 41.4 (6.9-127.8)... 5.0 9 7.4 (3.5-13.3)*** 19.7 2 24.0 (4.0-74.2)" 4.9 13 8.9 (4.9-14.7)*** 29.3
25-44(n=447) 4 6.2 (1.9-14.4)" 8.1 13 2.8(1.5-4.6)" 20.2 7 43.6 (18.8-84.4)... 16.5 24 4.2 (2.7-6.1)*** 44.1
45-54 (n=86) 5 5.3 (1.9-11.4)" 57.1 5 1.8 (0.6-3.8) 31.0 2 22.5 (3.7-69.4)" 26.9 13 3.3 (1.8-5.4)*** 126.6
.55 (n=129) 4 1.7 (0.5-3.9) 22.6 9 1.5 (0.7-2.6) 39.6 2 9.0 (1.5-27.8)' 24.6 17 1.9 (1.1-2.9)' 110.2
X2 trend 8.96** 9.95** 2.58 16.36***
aAbsolute excess risk per 10 000 person-years. *P<0.05; **P<0.01; ***P<0.01.
Table 5 Relative and absolute excess risks of second primary cancer by attained age
All other solid cancers except All malignancies except non-
Age (years) Lung cancer non-melanoma skin cancer Leukaemia melanoma skin cancer and
Hodgkin's disease
No. SIR (95%C) ARa No. SIR (95%Cl) ARa No. SIR (95% C) ARa No. SIR (95%C) AR'
<25 1 354 (20.2-1559)** 5.6 5 25.5 (9.1-54.7)*** 27.1 1 30.9 (1.8-136)* 5.5 7 27.5 (11.8-53.2)*** 38.0
(person-years = 1772)
25-44 2 10.0 (1.7-30.8)* 3.4 9 3.0 (1.4-5.3)** 11.1 5 36.0 (12.9-77.5)*** 9.2 16 4.4 (2.6-7.0)*** 23.5
(person-years = 5264)
45-54 5 10.1 (3.6-21.7)*** 37.4 7 2.7 (1.2-5.3)* 36.9 5 64.1 (23.0-138)*** 40.8 18 5.5 (3.3-8.4)*** 122.2
(person-years = 1205)
.55 7 2.1 (0.9-4.1) 29.0 15 1.7(1.0-2.7) 47.1 2 6.5 (1.1-20.2)* 13.3 26 2.0 (1.3-2.8)** 101.3
(person-years = 1275)
X2 trend 11.0*** 10.4** 3.8 21.3***
aAbsolute excess risk per 10 000. *P<0.05; **P<0.01; ***P<0.001.
Table 6 Relative risks of second cancer by duration since first treatment
All other solid cancers, All malignancies except
Duration (years) Lung cancer excluding non-melanoma Leukaemia Hodgkin's
skin cancer disease and
non-melanoma skin cancer
No. SIR (95% Cl) No. SIR (95% Cl) No. SIR (95% Cl) No. SIR (95% Cl)
0-4 2 1.3 (0.2-4.0) 14 2.8 (1.6-4.5)** 5 23.6 (8.5-50.8)*** 21 2.9 (1.9-4.4)***
(person-years = 4078)
5-9 6 5.7 (2.3-11.6)*** 9 2.3 (1.1-4.2)* 7 47.0 (20.2-90.9)*** 24 4.6 (3.0-6.6)***
(person-years = 2684)
10-14 6 7.8 (3.1-15.8)*** 5 1.7 (0.6-3.7) 0 - 12 3.0 (1.6-5.1)"
(person-years = 1656)
.15 1 1.6(0.1-7.0) 8 2.7(1.2-5.1)* 1 11.2(0.6-49.4) 10 2.6(1.3-4.6)"
(person-years = 1098)
*P<0.05; **P<0.01; ***P<0.001.
For each cancer site catergory shown, X21 trend not significant.
men. Relative risks ofsecond cancerwere greatly dependent on age
at first treatment (Table 4). The relative risk for cancer overall was
8.9 in patients treated before age 25, compared with less than 2 in
those treated at ages 55 and above. The age gradient was marked
and highly significant for solid cancers (P<0.001), and separately
for lung cancer and other solid cancers, but for leukaemia the
greatest relative risk was for treatment at ages 25-44, with a
diminishing relative risk for ages thereafter. For breast cancer (not
shown in table), the relative risks were 7.8 (1.3-24.2) for first
treatment before age 25 years, [32.8 (5.5-101.3) for first treatment
before age 20] and 1.2 (0.3-3.1) for first treatment at ages 25 and
above. The 20-year cumulative risk of breast cancer for women
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Table 7 Relative risks of second primary cancer in relation to specific chemotherapy treatments
All malignancies except non-melanoma
Treatment Solid cancers Leukaemia skin cancer and
Hodgkin's disease
No. RRa (95% Cl) No. RRa(95% Cl) No. RRa (95% Cl)
MOPPb 9 1.0 2 1.0 11 1.0
(person-years = 1406)
MOPP + otherc 0 - 5 8.0 (1.2-53.6)* 5 1.8 (0.6-5.5)
(person-years = 399)
ChIVPP 13 1.1 (0.3-4.2) 3 2.3 (0.2-22.7) 18 1.6 (0.5-4.6)
(person-years = 2751)
ChIVPP + otherd 2 0.5 (0.05-4.5) 1 1.4 (0.05-39.6) 3 0.7 (0.1-4.3)
(person-years = 471)
*P<0.05 aAdjusted for sex, age at first treatment, year of first treatment, duration since first treatment, number of cycles of chemotherapy
and radiotherapy. bBaseline group for calculation of relative risks. clncluding MOPP + ChIVPP. dExcluding ChIPP + MOPP. One second
malignancy occurred in patients treated solely with chemotherapy regimens other than those in the table (person-years = 469).
Table 8 Relative risks of second primary cancer in relation to number of cycles of chemotherapy
All malignancies except non-melanoma
No. of cycles Solid cancers Leukaemia skin cancer and
Hodkin's disease
No. RRa (95% Cl) No. RRa (95% Cl) No. RRa (95% Cl)
1-6 9 0.4 (0.1-1.3) 0 - 11 0.2 (0.1-0.6)"
(person-years = 3028)
7-12 11 1.1 (0.4-3.4) 5 0.4 (0.1-1.3) 16 0.7 (0.3-1.6)
(person-years = 1646)
>12b 5 1.0 6 1.0 11 1.0
(person-years = 822)
x2 trend 3.4 12.9*** 10.11**
**P<0.01 ***P<0.001 aAdjusted for sex, age at first treatment, year of first treatment, duration since first treatment, and radiotherapy.
bBaseline group for calculation of relative risks.
first treated before age 20 years was 4.1% (0.9-16.9), for those
first treated before age 25 years was 2.1% (0.5-9.0) and for those
first treated at age 25 years or more was 2.1% (0.7-6.5). All ofthe
breast cancers, except one in a woman first treated at age 61 with
chemotherapy plus radiotherapy to a tonsil, were after mantle
radiotherapy alone or, in one instance, with chlorambucil, vinblas-
tine, procarbazine and prednisone (ChIVPP).
When relative risks were considered in relation to attained age
(Table 5), there were large, highly significant trends ofgreater risk
at younger ages for all cancers and solid cancers, and a borderline
significant trend (P=0.05) for leukaemia. Absolute excess risks
were greater at ages 45 and above than at ages younger than this
but, otherwise, did not show a consistent gradient with age. In
treatment-specific analyses (not shown in table), aggregating the
categories used in Table 5 when necessary because of small
numbers, there were significant trends of increasing relative risk
with younger age for all cancers and for solid cancers, but not for
leukaemia, after radiotherapy and after combined-modality
therapy. For patients treated solely with chemotherapy, there was a
significant trend of greater risk with younger age (P=0.002) for
all cancers, relative risks for leukaemia of 79.6 (13.2-245.9;
P<0.001) for ages under 45 and 40.5 (10.1-105.0; P<0.001) for
ages 45 and above, and for solid cancers there were relative risks
of 4.3 (0.7-13.4) and 1.7 (0.6-3.8) for these age groups respec-
tively. The relative risk ofbreast cancer for women aged under 30
years was 43.0 (7.1-132.7; P<0.001), compared with 1.1 (0.3-2.9)
for women aged 30 years or more.
Relative risks of solid cancers remained increased 15 and more
years after first treatment (Table 6), and there was no significant
trend in risk with duration since first treatment. The leukaemia
relative risk reached a peak at 5-9 years after first treatment, and
then diminished greatly.
To explore further the relation of chemotherapy to risk of
second cancer we divided patients who had received any
chemotherapy into five groups according to the chemotherapeutic
agents received (Table 7) and into three groups by the number of
cycles of treatment (Table 8). We included patients in these
analyses irrespective ofwhether they had received radiotherapy in
addition to their chemotherapy, but we adjusted for whether or not
radiotherapy had been given. The analyses were based on 745
patients treated with chemotherapy; 58 patients were excluded for
whom there was insufficient information on dates of cycles of
chemotherapy. In categorizing the different treatment regimens,
we included with MOPP (mustine, vincristine, procarbazine and
prednisone), treatments in which vinblastine had been substituted
for vincristine, and with ChlVPP, treatments with vincristine
substituted for vinblastine. The most common regimens included
under 'other' chemotherapy were VEEP (vincristine, etoposide,
epirubicin, prednisolone), which had been received by 114
patients, melphalan plus BCNU plus etoposide (55 patients), and
ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) (47
patients). Leukaemia and solid cancer risks were not significantly
greater for patients treated with ChlVPP alone than for those
treated with MOPP alone (Table 7). Only one second cancer
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occurred in patients treated with chemotherapy that included
neither MOPP nor ChlVPP; 0.84 were expected in these patients
on the basis of South Thames general population cancer rates.
Most patients treated with nitrosoureas had also been treated
with MOPP or ChIVPP, but analyses of risk in relation to whether
nitrosoureas had ever been administered showed a large raised risk
of leukaemia: the relative risk of leukaemia for patients ever-
receiving nitrosoureas compared with those who received MOPP
alone was 38.5 (3.9-384.3), adjusted as in Table 7. There was
no raised risk of solid cancers after nitrosoureas compared
with MOPP alone, but only two solid cancers occurred after
nitrosourea treatment.
In the analyses of risk in relation to number of cycles of treat-
ment (Table 8), there was a significant (P=0.002) trend of greater
all-cancer risk with more cycles of treatment, which arose from a
significant (P=<0.001) trend for leukaemia (which occurred only
in patients receiving more than 6 cycles) and a non-significant
(P=0.07) trend in the same direction for solid malignancy.
DISCUSSION
The range of sites for which second cancer risk was raised in the
present data accords with findings from other cohorts of patients
treated for Hodgkin's disease (Kaldor et al, 1987; Tucker et al,
1988; Henri-Amar, 1992; Swerdlow et al, 1992; van Leeuwen et
al, 1994a). As in several recent studies where long-term follow-up
is available (Tucker et al, 1988; Henri-Amar, 1992; Swerdlow et
al, 1992; van Leeuwen et al, 1994a; Boivin et al, 1995) it is clear
in the present data that leukaemia risk is an early consequence of
chemotherapy, but one that diminishes beyond 10 years from
initial treatment. Solid cancer risks, however, continued to be
significantly raised even 15 years after treatment. In the long-term,
the solid cancer risk is the major second malignancy threat to
Hodgkin's disease patients. The relative risk of non-Hodgkin's
lymphoma in our data was similar to that in a large US study
(Boivin et al, 1995), although lower than in several other recent
studies (Henri-Amar, 1992; Swerdlow et al, 1992; van Leeuwen et
al, 1994a). We have checked that cases of non-Hodgkin's
lymphoma were not omitted from the analysis, and in the process
found five more cases currently excluded because they occurred in
overseas residents or occurred after the end ofthe analysed follow-
up. The cumulative risks of second malignancy need to be inter-
preted cautiously; because they take no account of the particular
background population risks of malignancy 'expected' in the study
area catchment population at the time of the follow-up, they
cannot directly be generalized to, or compared with, such risks in
other series ofpatients with Hodgkin's disease. Similarly, compar-
isons with other series need to take account of the age and sex
distributions of the different patient groups, which are powerful
influences on cumulative risk. It should also be noted that the
cumulative risks are conditional on remaining cancer free and
alive up to that point; they are not the percentage chance of devel-
oping the second cancer for a patient at the start of treatment. As
they involve competing risks, the cumulative risks for particular
cancers cannot be summed to give the cumulative risk for these
cancers in total (Clayton and Hills, 1993).
It is known from several studies (Boivin andO'Brien, 1988; Tucker
et al, 1988; Swerdlow et al, 1992; van Leeuwen et al, 1994), and
unsurprising in the light of the findings in other radiation-exposed
cohorts such as atomic bomb survivors (National Research Council,
1990), that solid cancer risks can be increased by radiotherapy.
Relative risks in patients treated with combined modalities are also
raised, and appear to be fairly similar to those for radiotherapy
alone. The risks after chemotherapy alone are much less clear,
however. There have been relatively small numbers of
person-years of long-term follow-up after chemotherapy without
radiotherapy in most cohorts yet published, and until recently the
power of such cohorts has been low and increased risk of solid
cancers has not been seen (Boivin and O'Brien, 1988; Young et al,
1990). Four recent studies have shown increased solid cancer risk
after chemotherapy (Kaldor et al, 1992; Swerdlow et al, 1992; Biti
et al, 1994; Boivin et al, 1995) while others did not (Abrahamsen et
al, 1993; van Leeuwen et al, 1994b). The reason for the difference
in findings is not obvious. The current results add to evidence for
an effect of chemotherapy on solid malignancy risks. The raised
risk in our data related entirely to MOPP and ChlVPP treatments,
but we had far too few person-years of follow-up after any other
specific treatment to determine risks for these other regimens. Risk
after ChlVPP was similar (non-significantly greater) to that after
MOPP in the present study. In Boivin's (1995) study, too, based
on larger numbers, risks after mustine and chlorambucil were
similar. In British National Lymphoma Investigation (BNLI) data
(Swerdlow et al, 1992), the solid cancer relative risk was similar for
mustine-containing and chlorambucil-containing combinations,
after adjustment for confounders. An effect of chemotherapy on
solid cancer risk is likely to be, at least to some extent, site specific.
We had too few second cancers to separate individual sites other
than lung, but for this site the borderline significant raised risk in
our data in relation to chemotherapy accords with significant raised
risks of this site in two previous studies (Kaldor et al, 1992;
Swerdlow et al, 1992), although not in others (van Leeuwen et al,
1994b; Boivin et al, 1995).
Information on solid cancer risk in relation to dosage would help
to clarify the possible aetiological role of chemotherapy for solid
malignancies, but there have been few data published on this. In
Kaldor's (1992) study, which was solely of lung cancer after
Hodgkin's disease, risk was not associated with the number of
cycles of MOPP. In BNLI data (Swerdlow et al, 1992) the number
ofcourses oftreatment showed no relation to solid malignancy risk,
but the great majority of the exposure was in the one-course cate-
gory. In the present data there was a trend in the direction of greater
risk with more cycles, although not quite significant (P=0.07).
As in several previous analyses (Pedersen-Bjegaard et al, 1987;
van der Velden et al, 1988; Henri-Amar et al, 1989; Kaldor et al,
1990; van Leeuwen et al, 1994b), risk of leukaemia increased
dramatically with dose or number of cycles of treatment and,
indeed, there were no leukaemias in the present study in patients
treated with only six cycles (one standard course) or less. As the
high risk of leukaemia after chemotherapy became clear, various
alternatives to the most used original combination, MOPP, have
been introduced, which might lead to a lower risk of leukaemia,
but studies have often had too few patients with any particular
other treatment to divide their analyses further than MOPP and
'other' chemotherapy. In the largest published analysis (Boivin et
al, 1995), leukaemia risk after chlorambucil was over twice that
after mustine, which is similar to the present results. Kaldor et al
(1990) found a lower risk after chlorambucil-procarbazine combi-
nations, but a greater risk after chlorambucil without procarbazine,
than after mustine-procarbazine combinations, although based on
few cases for the first two categories. Glicksman et al (1982)
found a large raised risk of leukaemia, based on three cases, in
patients receiving chlorambucil maintenance therapy but no
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mechlorethamine, and an SRR of 700 when mechlorethamine
induction plus chlorambucil maintenance was employed. In BNLI
data (Swerdlow et al, 1992), no leukaemias occurred after chlo-
rambucil, but only 0.06 were expected. Chlorambucil is less
acutely toxic and as effective as mustine in combination
chemotherapy (Selby et al, 1990), but it would appear not to be a
solution to the problem ofcarcinogenicity.
The decrease in relative risk of second cancers overall with
increasing age at first treatment accords with several previous
reports (Glicksman et al, 1982; Sont et al, 1992; Abrahamsen et al,
1993; Swerdlow et al, 1993). For leukaemia, previous studies
(Glicksman et al, 1982; van der Velden et al, 1988; Abrahamsen et
al, 1993; Swerdlow et al, 1993) agree with the present analyses
that relative risks diminish beyond middle age, and this has been
the case in analyses where ANLL or AML were analysed sepa-
rately (Glicksman et al, 1982; van der Velden et al, 1988), but
results have been variable with regard to the trend in risks at
younger ages offirst treatment.
Surprisingly, there are almost no previous data on relative
risks of solid malignancies in relation to age at first treatment
except for breast cancer. For this tumour, previous studies
concur that there is a large relative risk in follow-up beyond
15 years for women treated at young ages with chest radio-
therapy (Hancock et al, 1993; van Leeuwen et al, 1994a; Boivin
et al, 1995), but have differed on whether (Hancock et al, 1993)
or not (van Leeuwen et al, 1994a; Boivin et al, 1995) there is a
raised risk before 15 years of follow-up; in our data all of the
breast cancers occurred before 15 years from first treatment.
Careful clinical surveillance to detect breast cancers early is
needed in women treated young with mantle radiotherapy. The
only previous data on relative risks by age at first treatment for
solid cancers more generally appear to be those from the BNLI
(Swerdlow et al, 1993), which showed a significant trend of
increasing relative risk with decreasing age (although less steep
than in the present study) for non-lung solid cancers, and a non-
significant trend in the same direction (except that no cases
occurred under age 25) for lung cancer. The sole previous
analyses by attained age appear to be those on breast cancer risk
by Hancock et al (1993). These showed, as in the present data, a
large relative risk for women treated under age 30 years. Our
data set was not large enough to distinguish the separate contri-
butions of age at first treatment and attained age to solid cancer
risk, but the distinction is important to make. A relation of rela-
tive risk to young attained age would imply a decreasing relative
risk ofsecond malignancy for young patients as they grow older.
On the other hand, an effect based on age at first treatment
would imply, more worryingly, that relative risks will remain
very high in these patients as they age. The results by duration
since first treatment in our data and previously (Kaldor et al,
1987; Tucker et al, 1988; Henri-Amar, 1992; Swerdlow et al,
1992; van Leeuwen et al, 1994a) suggest that relative risks will
not cease to be raised simply because ofthe passage oftime, for
at least 10-20 years after first treatment. If large relative risks
remain as the patients grow older, they will translate into very
large absolute risks as the background risks rise with age.
The risks of second malignancies are small compared with the
benefits that intensive radiotherapy and chemotherapy have
brought to the treatment of Hodgkin's disease but further moni-
toring and refinement of treatments are needed to reduce these
adverse long-term side effects.
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